文献速递心脑血管急症

重组人尿激酶原治疗发病4.5小时内急性缺血性卒中的有效性与安全性:3期随机临床试验

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论发病4.5小时内急性缺血性卒中静脉溶栓,重组人尿激酶原在90天功能独立不劣于阿替普酶,症状性颅内出血相似,全身出血更少。

这项中国35个医疗中心开展的3期随机、阿替普酶对照、开放标签试验,于2018年5月至2020年5月纳入674例18至80岁、发病4.5小时内的急性缺血性卒中患者,1:1随机接受静脉重组人尿激酶原或阿替普酶。改良意向治疗人群663例中,90天改良Rankin量表评分0至1分的比例在重组人尿激酶原组为65.2%,阿替普酶组为64.3%(风险差0.89,95.4%CI -6.52至8.29),符合预先设定的非劣效界值(组间差异小于10%)。症状性颅内出血两组分别为1.5%和1.8%(P > .99),90天内全身出血重组人尿激酶原组25.8%低于阿替普酶组42.2%(P < .001),溶栓相关死亡两组均为1.5%(P > .99)。

要点

  • 主要终点90天改良Rankin量表评分0至1分:重组人尿激酶原组65.2% vs 阿替普酶组64.3%,风险差0.89(95.4%CI -6.52至8.29),满足非劣效界值(差异小于10%)。
  • 症状性颅内出血:重组人尿激酶原组1.5% vs 阿替普酶组1.8%,P > .99。
  • 90天内全身出血:重组人尿激酶原组25.8% vs 阿替普酶组42.2%,P < .001,阿替普酶组更常见。
  • 溶栓相关死亡:重组人尿激酶原组1.5% vs 阿替普酶组1.5%,P > .99。

适用人群与场景

  • 年龄18至80岁、诊断为急性缺血性卒中并在发病4.5小时内接受治疗的患者。

诊断标准与关键阈值

  • 非劣效界值:组间差异小于10%。
  • 主要终点:90天改良Rankin量表评分0至1分。

处置流程与药物剂量

  • 符合条件的患者按1:1随机接受静脉重组人尿激酶原或阿替普酶。

研究设计与关键结果

  • 研究类型:随机、阿替普酶对照、开放标签、3期临床试验;2018年5月至2020年5月在中国35个医疗中心开展;筛查684例,纳入674例。
  • 改良意向治疗人群663例:平均(SD)年龄61.00(10.20)岁,女性161例(24.3%);重组人尿激酶原组330例,阿替普酶组333例。
  • 基线美国国立卫生研究院卒中量表评分中位数(IQR)为6.00(5.00-9.00)。
  • 死亡23例,619例(93.4%)完成3个月随访。
  • 主要终点(90天改良Rankin量表评分0至1分):重组人尿激酶原组215例(65.2%) vs 阿替普酶组214例(64.3%),风险差0.89(95.4%CI -6.52至8.29)。
  • 症状性颅内出血:重组人尿激酶原组5例(1.5%) vs 阿替普酶组6例(1.8%)(P > .99)。
  • 90天内全身出血:阿替普酶组141例(42.2%)多于重组人尿激酶原组85例(25.8%)(P < .001)。
  • 90天内溶栓相关死亡:重组人尿激酶原组5例(1.5%) vs 阿替普酶组5例(1.5%)(P > .99)。

证据类型、等级与局限

  • 证据类型:随机、阿替普酶对照、开放标签、3期临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,发病4.5小时内急性缺血性卒中静脉重组人尿激酶原不劣于阿替普酶,症状性颅内出血发生率相似,全身出血更少。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that has shown promising findings in a phase 2 clinical trial in patients with acute ischemic stroke (AIS).

OBJECTIVE: To evaluate the efficacy and safety of rhPro-UK thrombolysis within 4.5 hours of symptom onset in patients with AIS.

DESIGN, SETTING, AND PARTICIPANTS: This randomized, alteplase-controlled, open-label, phase 3 clinical trial was conducted from May 2018 to May 2020 at 35 medical centers in China. A total of 684 patients were screened and 674 patients were enrolled. Included patients were aged 18 to 80 years with a diagnosis of AIS and received treatment within 4.5 hours of stroke onset. Data were analyzed from June to October 2020.

INTERVENTIONS: Eligible patients were randomly assigned (1:1) to receive intravenous rhPro-UK or alteplase.

MAIN OUTCOMES AND MEASURES: The primary objective was to assess whether rhPro-UK was noninferior to alteplase. The noninferiority margin was a between-group difference of less than 10%. The primary outcome was a modified Rankin Scale score of 0 to 1 at 90 days.

RESULTS: Among 663 patients in the modified intention-to-treat population (mean [SD] age, 61.00 [10.20] years; 161 females [24.3%]), there were 330 patients in the rhPro-UK group and 333 patients in the alteplase group. The median (IQR) baseline National Institutes of Health Stroke Scale score was 6.00 (5.00-9.00). There were 23 deaths, and 619 patients (93.4%) completed the 3-month follow-up. The primary outcome occurred in 215 patients (65.2%) in the rhPro-UK group and 214 patients (64.3%) in the alteplase group (risk difference, 0.89; 95.4% CI, -6.52 to 8.29). Symptomatic intracerebral hemorrhage occurred in 5 patients (1.5%) in the rhPro-UK group and 6 patients (1.8%) in the alteplase group (P > .99). Systemic bleeding within 90 days occurred more frequently in the alteplase group (141 patients [42.2%]) than the rhPro-UK group (85 patients [25.8%]) (P < .001). By 90 days, 5 thrombolysis-related deaths each had occurred in the rhPro-UK group (1.5%) and alteplase group (1.5%) (P > .99).

CONCLUSIONS AND RELEVANCE: This study found that intravenous rhPro-UK within 4.5 hours of AIS onset was noninferior to alteplase. The rhPro-UK group showed a similar rate of symptomatic ICH but fewer cases of systemic bleeding than the alteplase group.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03541668.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Song H, Wang Y, Ma Q, et al. Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37490291. doi:10.1001/jamanetworkopen.2023.25415

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。